Mdm2 Inhibitors And Combinations Thereof

Patent No. EP3340989 (titled "Mdm2 Inhibitors And Combinations Thereof") was filed by Novartis on Aug 24, 2016. The application was issued on Aug 16, 2023.

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

Company	Opposition Date	Representative
ELKINGTON AND FIFE	May 15, 2024	ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

Date
Description

Get instant alerts for new documents

Jun 16, 2025
Communication to the parties concerning the termination of the opposition proceedings (opponent)
Jun 16, 2025
Communication to the parties concerning the termination of the opposition proceedings (proprietor)
Mar 12, 2025
Brief communication - Opposition proceedings
Mar 12, 2025
Brief communication - Opposition proceedings
Mar 12, 2025
Decision of the Opposition Division and instruction
Mar 12, 2025
Decision revoking the European patent
Mar 12, 2025
Decision revoking the European patent
Mar 12, 2025
Grounds for the decision (Annex) - opposition
Mar 12, 2025
Means of redress
Feb 12, 2025
Scanned annex to a communication - opposition procedure
May 29, 2024
Communication of a notice of opposition and request to file observations
May 29, 2024
Notice of further oppositions to opponent(s)
May 21, 2024
Communication of a notice of opposition - first information to patent proprietor
May 15, 2024
(Electronic) Receipt
May 15, 2024
Any annexes (other than citation) to an opposition letter
May 15, 2024
Citation in opposition procedure - 001
May 15, 2024
Citation in opposition procedure - 002
May 15, 2024
Citation in opposition procedure - 003
May 15, 2024
Citation in opposition procedure - 004
May 15, 2024
Citation in opposition procedure - 005
May 15, 2024
Citation in opposition procedure - 006
May 15, 2024
Citation in opposition procedure - 007
May 15, 2024
Citation in opposition procedure - 008
May 15, 2024
Citation in opposition procedure - 010
May 15, 2024
Citation in opposition procedure - 010
May 15, 2024
Citation in opposition procedure - 011
May 15, 2024
Citation in opposition procedure - 012
May 15, 2024
Citation in opposition procedure - 013
May 15, 2024
Citation in opposition procedure - 014
May 15, 2024
Citation in opposition procedure - 015
May 15, 2024
Consolidated list of cited opposition documents
May 15, 2024
Notice of opposition
May 15, 2024
Notice of opposition
Nov 9, 2023
Letter relating to the revocation of the automatic debiting procedure
Sep 12, 2023
Refund of fees
Aug 29, 2023
Transmission of the certificate for a European patent pursuant to Rule 74 EPC
Jul 20, 2023
Decision to grant a European patent
Jul 7, 2023
(Electronic) Receipt
Jul 7, 2023
Filing of the translations of the claims
Jul 7, 2023
French translation of claims
Jul 7, 2023
German translation of the claims
Mar 16, 2023
Annex to the communication about intention to grant a European patent
Mar 16, 2023
Bibliographic data of the European patent application
Mar 16, 2023
Communication about intention to grant a European patent
Mar 16, 2023
Intention to grant (signatures)
Mar 16, 2023
Text intended for grant (clean copy)
Mar 16, 2023
Text intended for grant (version for approval)
Mar 2, 2023
Request for correction of obvious mistakes allowed
Dec 1, 2021
(Electronic) Receipt
Dec 1, 2021
Letter accompanying subsequently filed items
Dec 1, 2021
Request for correction of errors in filed documents
Aug 17, 2021
Bibliographic data of the European patent application
Aug 17, 2021
Communication about intention to grant a European patent
Aug 17, 2021
Intention to grant (signatures)
Aug 17, 2021
Text intended for grant (clean copy)
Aug 17, 2021
Text intended for grant (version for approval)
Jul 26, 2021
(Electronic) Receipt
Jul 26, 2021
Amended claims with annotations
Jul 26, 2021
Claims
Jul 26, 2021
Letter accompanying subsequently filed items
Jul 26, 2021
Request for correction/amendment of the text proposed for grant sent from 01.04.2012
Jul 8, 2021
Bibliographic data of the European patent application
Jul 8, 2021
Communication about intention to grant a European patent
Jul 8, 2021
Intention to grant (signatures)
Jul 8, 2021
Text intended for grant (clean copy)
Jul 8, 2021
Text intended for grant (version for approval)
Mar 2, 2021
(Electronic) Receipt
Mar 2, 2021
Amended claims with annotations
Mar 2, 2021
Amended description with annotations
Mar 2, 2021
Claims
Mar 2, 2021
Description
Mar 2, 2021
Letter accompanying subsequently filed items
Mar 2, 2021
Reply to communication from the Examining Division
Feb 22, 2021
Annex to the communication
Feb 22, 2021
Communication from the Examining Division
Sep 10, 2020
(Electronic) Receipt
Sep 10, 2020
Amended claims with annotations
Sep 10, 2020
Claims
Sep 10, 2020
Letter accompanying subsequently filed items
Sep 10, 2020
Reply to communication from the Examining Division
Jul 10, 2020
Annex to the communication
Jul 10, 2020
Communication from the Examining Division
Dec 6, 2019
(Electronic) Receipt
Dec 6, 2019
Amended claims with annotations
Dec 6, 2019
Annex
Dec 6, 2019
Claims
Dec 6, 2019
Letter accompanying subsequently filed items
Dec 6, 2019
Reply to communication from the Examining Division
Sep 20, 2019
Grant of extension of time limit (examination procedure)
Sep 17, 2019
(Electronic) Receipt
Sep 17, 2019
Letter accompanying subsequently filed items
Sep 17, 2019
Request for extension of time limit to communication from the Examining Division
Jun 5, 2019
Annex to the communication
Jun 5, 2019
Communication from the Examining Division
May 29, 2019
Examination started
Jun 6, 2018
Notification on forthcoming publication of bibliographic data
Apr 11, 2018
Communication regarding comments on written opinion/amendment of application/payment of claims fee
Apr 9, 2018
Communication to designated inventor
Apr 9, 2018
Communication to designated inventor
Apr 9, 2018
Communication to designated inventor
Apr 9, 2018
Communication to designated inventor
Mar 21, 2018
Copy of the international preliminary report on patentability
Jan 31, 2018
(Electronic) Receipt
Jan 31, 2018
Amended claims filed after receipt of (European) search report
Jan 31, 2018
Amended claims with annotations
Jan 31, 2018
Request for entry into the European phase
Jan 12, 2018
Information on entry into European phase
Mar 28, 2017
Priority document (electronically transmitted)
Mar 28, 2017
Priority document (electronically transmitted)
Mar 28, 2017
Priority document (electronically transmitted)
Mar 9, 2017
Copy of the international search report
Mar 9, 2017
Published international application - A1
Nov 7, 2016
ISR: cited documents
Nov 4, 2016
Written opinion of the ISA, boxes No. I to VIII
Nov 4, 2016
Written opinion of the ISA, cover sheet
Nov 4, 2016
Written opinion of the ISA, supplemental box
Sep 20, 2016
Notification of receipt of Search copy
Sep 6, 2016
Abstract
Sep 6, 2016
Annex
Sep 6, 2016
Annex
Sep 6, 2016
Claims
Sep 6, 2016
Description
Sep 6, 2016
Drawings
Sep 6, 2016
Request form for international application (copy for ISA/EP)

EP3340989

NOVARTIS

Application Number: EP16760803A
Filing Date: Aug 24, 2016
Status: Revoked; Jun 13, 2025
Publication Date: Aug 16, 2023
External Links: Slate, EP3340989B1, Google Patents

IP Verse

Mdm2 Inhibitors And Combinations Thereof

Patent Summary

Patent Family

Patent Oppositions

Dossier Documents

EP3340989